title: Manserin as a novel histochemical neuroendocrine marker in prostate cancer.
abstract: OBJECTIVE
  To investigate the presence of manserin in human prostate cancers and to correlate manserin expression with pathologic outcomes and progression-free survival.
  
  
  METHODS
  Eighty-seven patients with recent prostate cancer were classified into 4 groups based on Gleason score, and manserin immunohistochemistry was correlated with Gleason sum grade. To investigate the validity of manserin as a prognostic factor, the Cox proportional hazards regression model was performed on 48 patients in our cohort with T3 or T4 prostate cancer who were initially treated with androgen deprivation therapy.
  
  
  RESULTS
  The manserin-positive rates of patients with Gleason sums of 6, 7, 8, and ≥9 were 0%, 20.0%, 35.0%, and 48.1%, respectively. Manserin-positive rates were positively correlated with Gleason sums (P = 0.0001). Median times to cancer progression in groups with (n = 8) and without (n = 40) manserin expression were 8 months and 28 months, respectively (P = 0.01). Univariate Cox analysis revealed that manserin expression, clinical stage T4, and high Gleason sum were significantly associated with progression. Multivariate analysis revealed that only 2 factors, manserin expression (hazard ratio (HR) 4.99, P = 0.01) and clinical stage T4 (HR 4.77, P = 0.03), were independent risk factors for progression.
  
  
  CONCLUSIONS
  This is the first report of manserin expression in human prostate cancers. Manserin may serve as a marker of prostate cancer progression.
authors.affiliation: Department of Nephro-Urologic Surgery and Andrology, Mie University Graduate School of Medicine, Mie, Japan.
authors.forename: Kouhei
authors.initials: K
authors.lastname: Nishikawa
authors.forename: Norihito
authors.initials: N
authors.lastname: Soga
authors.forename: Kenichiro
authors.initials: K
authors.lastname: Ishii
authors.forename: Manabu
authors.initials: M
authors.lastname: Kato
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Iwamoto
authors.forename: Yasuhide
authors.initials: Y
authors.lastname: Hori
authors.forename: Michiru
authors.initials: M
authors.lastname: Etoh
authors.forename: Takeshi
authors.initials: T
authors.lastname: Ohkawara
authors.forename: Tomomi
authors.initials: T
authors.lastname: Yamada
authors.forename: Katsunori
authors.initials: K
authors.lastname: Uchida
authors.forename: Hideaki
authors.initials: H
authors.lastname: Kise
authors.forename: Kiminobu
authors.initials: K
authors.lastname: Arima
authors.forename: Masaaki
authors.initials: M
authors.lastname: Narita
authors.forename: Taizo
authors.initials: T
authors.lastname: Shiraishi
authors.forename: Yoshiki
authors.initials: Y
authors.lastname: Sugimura
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000378:metabolism*; D015331:Cohort Studies; D018450:Disease Progression; D018572:Disease-Free Survival; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D060787:Neoplasm Grading; D009479:Neuropeptides / Q000378:metabolism*; D010446:Peptide Fragments / Q000378:metabolism*; D016016:Proportional Hazards Models; D011467:Prostate / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000378:metabolism*; D029607:Seminal Vesicle Secretory Proteins / Q000378:metabolism*; D013997:Time Factors
chemical_list: D000726:Androgen Antagonists; D014408:Biomarkers, Tumor; D009479:Neuropeptides; D010446:Peptide Fragments; D029607:Seminal Vesicle Secretory Proteins; C586702:manserin protein, human